Usual adult dose is 2 capsules by mouth daily twice daily, or as prescribed by a licensed medical practitioner. Nexiva is an orally administered prescription probiotic formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed.
Nexiva Probiotic Capsules
Dispensed by Prescription
Nexiva Probiotic Capsules are clear capsules dispensed in plastic bottles of 30 ct.
85622-0112-30
Reserved for Professional Recommendation
Nexiva Probiotic Capsules should be administered under the supervision of a licensed medical practitioner.
This listed product is not a National Drug Code, but instead has merely been formatted to comply with standard industry practice for pharmacy and insurance computer systems.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on therapeutic equivalence.
Manufactured for:
Blue Heron Pharmaceuticals
Lutz, FL 33559
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
As with any supplement, if you are pregnant, nursing, taking medication, or have a medical condition, ask a health professional before taking this product.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Usual adult dose is 2 capsules by mouth daily twice daily, or as prescribed by a licensed medical practitioner.
Nexiva is an orally administered prescription probiotic formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed.
CONTRAINDICATIONS
This product is contraindicated in patients with known hypersensitivity to any of the ingredients.
PRECAUTIONS
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
ADVERSE REACTIONS
Allergic sensitizations have been reported following oral administration of folic acid. Consult your physician immediately if adverse side effects occur.
KEEP OUT OF THE REACH OF CHILDREN.
STORAGE:
Handling (before opening):
Product is sensitive to moisture and heat. Keep bottle tightly closed in a dry, cool place. Store at 200C to 250C (680F to 770F).
Handling (after opening):
Store in the refrigerator after opening, DO NOT FREEZE. Store at 20C to 80C (350F to 460F).
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 2166201 | Bifidobacterium animalis 7.5 Billion UNT / Lactobacillus acidophilus 8 Billion UNT Oral Capsule | PSN | 1 |
| 2166201 | Bifidobacterium animalis 7500000000 UNT / Lactobacillus acidophilus 8000000000 UNT Oral Capsule | SCD | 1 |
| 2166201 | Bifidobacterium animalis 7.5 Billion UNT / Lactobacillus acidophilus 8 Billion UNT Oral Capsule | SY | 1 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 85622-112-30 | NEXIVA | 30 in 1 BOTTLE | CAPSULE | 30 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 85622-112-30 | EA - Each | 85622-112 | b158e0a4-4204-4e2a-a63a-b6b0e32d1309 | 1 | 2026-03-17 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 85622-112 | 85622-112-30 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LACTOBACILLUS ACIDOPHILUS | 1PRR1V42V5 | ACTIB |
| BIFIDOBACTERIUM ANIMALIS LACTIS | 5307V7XW8I | ACTIM |
Adverse event summaries are temporarily unavailable. Other product information remains available.